Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tango Therapeutics, Inc. (TNGX)
:TNGX
RESEARCH TOOLSreports
Holding TNGX?
Track your performance easily
TNGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.59 - $13.01
Previous CloseN/A
Volume187.94K
Average Volume (3M)1.27M
Market Cap
$298.62M
Enterprise Value$579.86M
Total Cash (Recent Filing)$485.25M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Mar 31, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding107,417,816
10 Day Avg. Volume1,012,341
30 Day Avg. Volume1,269,170
Standard Deviation0.29
R-Squared0.03
Alpha-0.00524
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.02
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.94
Enterprise Value/Revenue13.37
Enterprise Value/Gross Profit15.87
Enterprise Value/Ebitda-4.51
Forecast
1Y Price Target
$11.67Price Target Upside324.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Tango Therapeutics News
PremiumCompany Announcements
Tango Therapeutics Highlights Breakthroughs in Cancer Treatment
PremiumCompany Announcements
Tango Therapeutics Advances Cancer Treatment Pipeline
Bulls Say, Bears Say
Bulls Say
Combination TreatmentsTango is planning to evaluate TNG462 in combination with other treatments, supported by preclinical data showing enhanced anti-tumor activity.
Drug EfficacyTNG462 is seen as having the potential to be differentiated as best-in-class, reflecting the drug's encouraging preclinical properties.
Stock PriceMarket overreaction provides attractive stock price entry point.
Bears Say
Clinical Trial DelaysThe first launch of TNG462 has been delayed by two years to 2028 to more accurately reflect the company's latest clinical trial plans.
Investor DisappointmentInvestors were disappointed that the company did not provide efficacy for the 39 evaluable patients at active doses.
Product Efficacy ConcernsTango's PRMT5 inhibitors do not appear to be as selective for MTAP-null vs. MTAP-WT tumors as BMS-986504.
---
Ownership Overview
50.83% Insiders
12.00% Mutual Funds
0.01% Other Institutional Investors
28.34% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TNGX FAQ
What was Tango Therapeutics, Inc.’s price range in the past 12 months?
Tango Therapeutics, Inc. lowest stock price was $2.58 and its highest was $13.01 in the past 12 months.
What is Tango Therapeutics, Inc.’s market cap?
Tango Therapeutics, Inc.’s market cap is $298.62M.
When is Tango Therapeutics, Inc.’s upcoming earnings report date?
Tango Therapeutics, Inc.’s upcoming earnings report date is Mar 31, 2025 which is in 72 days.
How were Tango Therapeutics, Inc.’s earnings last quarter?
Tango Therapeutics, Inc. released its earnings results on Nov 06, 2024. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.367 by $0.097.
Is Tango Therapeutics, Inc. overvalued?
According to Wall Street analysts Tango Therapeutics, Inc.’s price is currently Undervalued.
Does Tango Therapeutics, Inc. pay dividends?
Tango Therapeutics, Inc. does not currently pay dividends.
What is Tango Therapeutics, Inc.’s EPS estimate?
Tango Therapeutics, Inc.’s EPS estimate is -0.34.
How many shares outstanding does Tango Therapeutics, Inc. have?
Tango Therapeutics, Inc. has 107,417,816 shares outstanding.
What happened to Tango Therapeutics, Inc.’s price movement after its last earnings report?
Tango Therapeutics, Inc. reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.367. Following the earnings report the stock price went down -37.452%.
Which hedge fund is a major shareholder of Tango Therapeutics, Inc.?
Among the largest hedge funds holding Tango Therapeutics, Inc.’s share is Deerfield Management Company, LP. It holds Tango Therapeutics, Inc.’s shares valued at 12M.
---
Tango Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (324.36% Upside)
$11.67 (324.36% Upside)
Blogger Sentiment
Bullish
TNGX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 328.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $28.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.15%
12-Months-Change
Fundamentals
Return on Equity
-48.80%
Trailing 12-Months
Asset Growth
-17.70%
Trailing 12-Months
Company Description
Tango Therapeutics, Inc.
BCTG Acquisition Corp is a blank check company.
---
TNGX Stock 12 Month Forecast
Average Price Target
$11.67
▲(324.36% Upside)
Technical Analysis
Precision BioSciences
―
Fate Therapeutics
―
Rocket Pharmaceuticals
―
Editas Medicine
―
Crispr Therapeutics AG
―
Bluebird Bio
―
Best Analysts Covering TNGX
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+6.60%
reiterated a buy rating 2 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +6.60% per trade.
---